Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
91.12
-4.24 (-4.45%)
At close: Jul 27, 2026, 4:00 PM EDT
92.38
+1.26 (1.38%)
After-hours: Jul 27, 2026, 7:51 PM EDT
Corcept Therapeutics Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Corcept Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $92. The average 1-year stock price forecast is 0.97% higher than the current stock price, while the lowest is $50 (-45.13%) and the highest is $135 (+48.16%).
Price Target: $92 (+0.97%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Corcept Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 2 | 2 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Sell Downgrades $50 | Sell | Downgrades | $50 | -45.13% | Jul 27, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $88 | Buy | Maintains | $88 | -3.42% | Jul 24, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $135 | Buy | Maintains | $135 | +48.16% | Jul 9, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $95 | Buy | Maintains | $95 | +4.26% | Jun 1, 2026 |
| UBS | UBS | Buy Upgrades $72 | Buy | Upgrades | $72 | -20.98% | May 13, 2026 |
Financial Forecast
Revenue This Year
1.01B
from 761.41M
Increased by 32.13%
Revenue Next Year
1.50B
from 1.01B
Increased by 49.08%
EPS This Year
0.56
from 0.82
Decreased by -32.11%
EPS Next Year
3.21
from 0.56
Increased by 476.05%
EPS and Forward PE are based on non-GAAP adjusted numbers.